

Longevity Company Report

August 2022

Table of Contents

A brief look at what we will discuss in this report

01 Introduction

02 Welcome To Spannrr


03 Public Companies

04 Public Company Insights

05 Watchlist

06 Private Companies

07 Closing Thoughts



01

Introduction

Hello.

Welcome to Spannr's first longevity company report, where we identify the top public and private for-profit organizations working to extend healthy human lifespans.

In conjunction with the launch of the [Longevity Stock Index](#), Spannr's proprietary index allowing users to track broader price action trends in real-time, this report is intended to guide readers through the complicated world of longevity biotechnology investing.

Below, you will find a variety of publicly-traded companies that investors can gain exposure to today. To help paint a clearer picture of today's public market environment, we have also provided company descriptions, core focuses, and stock information such as market capitalization, ticker symbols, charts, and exchange data.

Furthermore, we have included information on the top private companies in the space. That's because, as many of us know, the public market isn't the only place one can deploy their capital. Please note that there are dozens of private companies that are not featured in this report. If you are an accredited investor, you can join [Spannr Ventures](#) to participate in investment opportunities that may include companies in this report or with companies that are still in stealth.

02

**Welcome to
Spannr**

Within the longevity community, those who are interested in increasing their healthspan or lifespan are called “spanners.” We’ve taken a slight twist on this name, to represent the enormous number of people around the world who want to live healthier, longer lives.

The Spannr team is currently building the world's most comprehensive source of longevity news, information, and insights. While we aim to cater to the existing community of longevity professionals and enthusiasts, our goal is to help spread awareness and attract new interest from outside of the small community.

Our written content, website resources, and future products are being built with the idea that the longevity ecosystem needs to be simplified and approachable for everyone.

The team behind Spannr is currently working on a variety of projects that will be released in the coming months. In the short term, this includes our database which will offer insights beyond science and research. Topics such as events, jobs, fundraising rounds, investors, and much more will all be included within this database. By quantifying the longevity ecosystem, our aim is to bring attention and display compelling opportunities to those who may not understand how to get involved in this exciting world.

Currently, Spannr offers a weekly newsletter that is already read by the top longevity industry leaders, VC funds, and policy makers. If you haven’t already, just [click here](#) to subscribe. We’ve also just launched the [Longevity Stock Index](#), which is the first tool that enables investors to see the blended performance of the longevity biotech sector.

03

Public Longevity Companies

Denali Therapeutics

Denali Therapeutics is a biotechnology company with a goal to discover, develop, and deliver therapeutics that target neurodegenerative diseases. With significant unmet need and currently few effective therapeutics options available to patients with neurodegenerative disease, Denali is helping lead the way for potential drug targets while enabling better patient selection.



**All data displayed in this report is based off numbers from August 2, 2022. Numbers, specifically market cap, will vary over time.*

Location

**California,
USA**

Ticker

**DNLI
NYSE**

Market Cap

\$4.3B

Focus

Autophagy

Recursion Pharmaceuticals

Recursion Pharmaceuticals is a clinical-stage biotechnology company with a focus on drug discovery via Artificial Intelligence and Machine Learning. Their diverse technological platform, Recursion Operating System (OS), enables the company to map and navigate hundreds of billions of biological and chemical relationships within one of the world's largest proprietary biological and chemical datasets, the Recursion Data Universe.



Location

Utah, USA

Ticker

RXXRX

NASDAQ

Market Cap

\$1.4B

Focus

AI/ML

Alector

Alector is a biotechnology company that is using their insights into human genetics, immunology, and neuroscience to develop new therapeutic treatments for neurodegenerative disease. The company currently has an industry leading portfolio of immuno-neurology programs that are designed to equip and empower the brain's immune system to fight disease.



Location

**California,
USA**

Ticker

ALEC
NASDAQ

Market Cap

\$854M

Focus

**Extracellular
Aggregates**

Geron

Geron is a late-stage clinical biopharmaceutical company focused on developing and possibly commercializing a first-in-class telomerase inhibitor, Imetelstat, which is essentially an experimental drug targeting a hallmark of cancer. The commitment to improve and extend patients' lives by targeting telomerase and changing the course of these diseases is highlighted by the company's two ongoing Phase 3 clinical trials.



Location

**California,
USA**

Ticker

**GERN
NASDAQ**

Market Cap

\$713M

Focus

Telomeres

Mesoblast

Mesoblast is a biotechnology company focused on developing and commercializing drugs to treat complex disease resistant to the conventional standard of care and where inflammation plays a central role. Its proprietary technology platform is used for innovative allogeneic cellular medicines. Mesoblast has developed mesenchymal lineage adult stem cells (MLCs) that play vital roles in maintaining tissue health and are found in multiple tissues.



Location

**Melbourne,
Australia**

Ticker

MESO
NASDAQ

Market Cap

\$419M

Focus

**Regenerative
Medicine**

Celularity

As a clinical-stage biotechnology company, Celularity develops allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases.



Location

**New Jersey,
USA**

Ticker

CELU
NASDAQ

Market Cap

\$416M

Focus

**Regenerative
Medicine**

Humacyte

Humacyte is a biotechnology company that develops and manufactures bioengineered off-the-shelf, universally implantable human tissues. The regenerative vascular conduit, Humacyte Human Acellular Vessel (HAV), is currently in various stages of clinical trials that are targeting multiple vascular applications. Their platform technology also has potential applications and solutions for complex organ disease, including replacement tissues or organs for coronary grafts, pediatric heart surgery, and Type 1 diabetes treatment.



Location

**N. Carolina,
USA**

Ticker

HUMA
NASDAQ

Market Cap

\$347M

Focus

Tissue Engineering

Scholar Rock

Scholar Rock is a biopharmaceutical company committed to developing innovative drugs for treating serious conditions characterized by protein growth factor signaling. The company has developed a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. These developments could enable other novel product developments to help transform the lives of patients suffering from a wide range of diseases.



Location

Mass, USA

Ticker

SRRK
NASDAQ

Market Cap


\$336M

Focus

**Regenerative
Medicine**

Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company that develops novel cell therapies addressing unmet medical needs. Lineage offers programs that are based on proprietary cell-based technologies that also contain capabilities for associated development and manufacturing. From this platform, they create, develop, and manufacture human cells with specialized anatomical and physiological functions that allow either replacement or support for degenerative diseased or traumatically injured existing cells.



Location

**California,
USA**

Ticker

**LCTX
NYSE**

Market Cap

\$268M

Focus

**Regenerative
Medicine**

Vigil Neuroscience

Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil utilizes the tools of modern neuroscience drug development across multiple therapeutic modalities in efforts to develop precision-based therapies to improve the lives of patients and their families.



Location

Mass, USA

Ticker

VIGL
NASDAQ

Market Cap

\$182M

Focus

**Regenerative
Medicine**

Precision BioSciences

Precision BioSciences is a clinical-stage biotechnology company dedicated to improving life with its proprietary ARCUS genome editing platform – a genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist.



Location

**N. Carolina,
USA**

Ticker

**DTIL
NASDAQ**

Market Cap

\$160M

Focus

**Cellular
Reprogramming**

MyMD

MyMD is a clinical-stage pharmaceutical company with a focus on developing drug products targeting aging and age-related disease, including autoimmune disease, chronic pain, anxiety, and sleep disorders. The company's two broad drug platforms include MYMD-1, a novel therapeutic that impacts multiple conditions that are related to immunometabolic dysregulation positively, and Supera-CBD, which is a synthetic cannabidiol that has better bioavailability and potency than compared botanical products.



Location

**Maryland,
USA**

Ticker

**MYMD
NASDAQ**

Market Cap


\$154M

Focus

Pharmaceuticals

Longeveron

As a clinical-stage biotechnology company, Longeveron develops cellular therapies for chronic diseases associated with aging and other additional life-threatening conditions. Lomecel-B, the company's lead investigational product, derives from culture-expanded medicinal signaling cells (MSCs) isolated from the donated bone marrow of young healthy adults. By utilizing young healthy donors, Longeveron has a goal to develop safe and effective cell therapies for some of the most extreme and difficult conditions that are associated with aging.



Location

Florida, USA

Ticker

LGVN
NASDAQ

Market Cap

\$127M

Focus

**Regenerative
Medicine**

ChromaDex

ChromaDex is a bioscience company dedicated to the support and development of healthy aging. The company has initiatives in research related to nicotinamide adenine dinucleotide (NAD+), which is found in every cell as we age. Being known for its active role in cellular energy production, NAD+ is now thought to hold an important role in healthy aging, as it is an essential coenzyme and key regulator of cellular metabolism and is required for efficient and proper mitochondrial function.



Location

**California,
USA**

Ticker

CDXC
NASDAQ

Market Cap

\$114M

Focus

Supplements

Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through a licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the FDA and the EMA for the treatment of amyotrophic lateral sclerosis (ALS).



Location

**New York,
USA**

Ticker

**BCLI
NASDAQ**

Market Cap

\$100M

Focus

**Regenerative
Medicine**

Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company is developing a cell therapy product called MultiStem, which is a patented, adult-derived “off-the-shelf” stem cell product, initially for neurological, inflammatory and immune, and cardiovascular disease. Athersys has several ongoing clinical trials evaluating this potential regenerative medicine product.



Location

Ohio, USA

Ticker

ATHX
NASDAQ

Market Cap

\$69M

Focus

**Regenerative
Medicine**

Miromatrix

Miromatrix is a biotechnology company that is developing bioengineered organs for transplantation. The company has over 118 issued patents worldwide with a technology that can be applied across a range of donor needs. They are focused on developing kidneys (MiroKidney) and livers (MiroLiver) that are transplantable with additional plans for other critical organs like lungs, pancreases and hearts. The company's technology has been tested extensively both in preclinical and animal studies and has been cleared by the FDA in a previously commercialized matrix product.



Location

**Minnesota,
USA**

Ticker

**MIRO
NASDAQ**

Market Cap

\$59M

Focus

**Organ Transplant
Therapy**

Cognition Therapeutics

Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics targeting age-related degenerative diseases and disorders specific to the central nervous system (CNS) and retina. The company has experience in the sigma-2 receptor (S2R), which is expressed by multiple cell types, including neuronal synapses. It also acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina.



Location

**New York,
USA**

Ticker

CGTX
NASDAQ

Market Cap

\$48M

Focus

**Cellular
Reprogramming**

UNITY Biotechnology

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefits in age-related ophthalmologic and neurologic diseases.



Location

California,
USA

Ticker

UBX
NASDAQ

Market Cap

\$45M

Focus

Senescent Cells

Pluristem Therapeutics

Pluristem is a clinical-stage regenerative medicine company that is using placental cells and a proprietary 3D-technology platform for developing cell therapies for ailments such as inflammation, muscle injuries, hematological disorders, and radiation exposure.



Location

Haifa, Israel

Ticker

PLUR
NASDAQ

Market Cap

\$35M

Focus

**Regenerative
Medicine**

AgeX

AgeX is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeX's PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. The company has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.



Location

**California,
USA**

Ticker

AGE
NYSE Arca

Market Cap

\$26M

Focus

**Cellular
Reprogramming**

Organovo

Organovo is an early-stage biotechnology company that is developing and utilizing highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The company’s proprietary technology is being used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Their initial focus is on the intestines and currently have ongoing development efforts in ulcerative colitis (UC) and Crohn’s disease (“CD”) for 3D tissues.



Location

**California,
USA**

Ticker

ONVO
NASDAQ

Market Cap

\$26M

Focus

Tissue Engineering

Alterity

Alterity is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes.



Location

**Victoria,
Australia**

Ticker

**ATHE
NASDAQ**

Market Cap

\$24M

Focus

**Regenerative
Medicine**

Stealth Biotherapeutics

Stealth BioTherapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. The company believes its lead product candidate, elamipretide, has the potential to treat ophthalmic diseases entailing mitochondrial dysfunction, rare neuromuscular disorders, and rare cardiomyopathies.



Location

Mass, USA

Ticker

MITO
NASDAQ

Market Cap


\$22M

Focus

Mitochondria

Yumanity Therapeutics

Yumanity is a biopharmaceutical company specifically focused on discovering and developing innovative novel therapies to treat neurodegenerative diseases with a critical unmet need. Target conditions include large or orphan disease markets, such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, ALS, and frontotemporal lobar dementia.



Location

Mass, USA

Ticker

YMTX
NASDAQ

Market Cap

\$17M

Focus

**Regenerative
Medicine**

CohBar

CohBar is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. The company is utilizing its Mito+ platform to identify and develop modified versions of natural peptides called analogs to treat a variety of serious conditions, with a focus on diseases involving inflammation and fibrosis.



Location

**California,
USA**

Ticker

**CWBR
NASDAQ**

Market Cap

\$16M


Focus

Mitochondria


04

Public Company Insights


Thematic Breakdown



Location Breakdown



Market Cap. Breakdown



05

Watchlist

To be clear, not every single longevity-related public company made it in the first iteration of our [Longevity Stock Index](#). Currently, for example, the Longevity Stock Index only lists public companies that are trading on US exchanges, leaving out a few international stocks. Furthermore, there have been a couple of companies that have recently IPO'd that will be considered for inclusion during our next index rebalancing.

Our goal, at the end of the day, is to create an index that best represents the public longevity market. And while it may not be perfect today, we'll aim to continuously improvise and fine tune our list of constituents as time passes with quarterly rebalancing.

For further information on our Index methodology, please visit [this page](#) to learn more. Also, if you have any feedback or suggestions, please don't hesitate to reach out to us at admin@spannr.com.

That said, just because a company isn't listed on our Longevity Stock Index today, does not mean they can't be listed at a future date. Thus, despite these companies being listed in the "watchlist" of this report, they are still viable public market plays. In other words, the following stocks should certainly still be on every investor's radar when seeking for greater exposure to the industry.

Company	Location	Ticker	Market Cap	IPO Date	Focus
Genflow Biosciences	London, UK	LON:GENF	\$8.04M	Jan 17, 2022	Gene Therapy for pets and humans
GenSight Biologics	Paris, France	EPA: SIGHT	\$127.1M	July 14, 2016	Gene Therapy
Biophytis	Paris, France	NASDAQ: BPTS	\$14.18M	Feb 10, 2021	Regenerative Medicine
Human Longevity*	California, USA	NYSE: FACT*	TBD*	TBD*	Health Intelligence
HCW Biologics	Florida, USA	NASDAQ: HCWB	\$83.41M	July 19, 2021	Immunosenescence
MAIA Biotechnology	Illinois, USA	NYSE: MAIA	\$69.1M	August 1, 2022	Telomeres
United Therapeutics	Maryland, USA	NASDAQ: UTHR	\$10.16B	June 17, 1999	Gene Therapy / Organ Manufacturing
Vaxxinity	Texas, USA	NASDAQ: VAXX	\$243.29M	Nov 11, 2021	Immunotherapy
Cyclo Therapeutics	Florida, USA	NASDAQ: CYTH	\$16.16M	Dec 9, 2020	Cellular Reprogramming
Frequency Therapeutics	Mass, USA	NASDAQ: FREQ	\$68.50M	Oct 3, 2019	Regenerative Medicine

*In June, 2022 Human Longevity reported the intention to go public through a SPAC with Freedom Acquisition I



06

Private Longevity Companies

Calico

Calico, an Alphabet subsidiary, is a research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. Calico will use that knowledge to devise interventions that enable people to lead longer and healthier lives.



Location	Founded	Funding	Focus
California, USA	2013	Unknown	AI/ML

Juvenescence

Juvenescence is on a mission to transform what aging means to the world. Science around aging is accelerating at an extraordinary pace, so the company set out to further that science and disrupt the thinking and behavior around aging. That's why Juvenescence built a coalition of the best scientists, physicians, and investors to create cutting-edge therapies and products that will empower people to chart their own path forward.



Location	Founded	Funding	Focus
Dublin, Ireland	2016	\$219.2M	DisCo



Rejuveron

Rejuveron invests in programs, co-founded with world-class scientific entrepreneurs, each focusing on one or more of the hallmarks of aging, to turn their discoveries into medicines. The company's drug discovery and development team, together with a specialist scientific advisory network, provide guidance on bringing transformative ideas into the clinic. The Rejuveron programs share lab space, equipment, and offices, with plug-and-play access to a state-of-the-art research infrastructure.

rejuveron

Location	Founded	Funding	Focus
Zurich, Switzerland	2019	\$63.9M	DisCo

Cambrian Biopharma

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Their approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life as we age.



Location	Founded	Funding	Focus
New York, USA	2019	\$160M	DisCo



BioAge Labs

BioAge is a platform-driven, clinical-stage biotechnology company that is mapping human aging to develop a pipeline of therapies that treat disease and extend healthy lifespan. Their proprietary human-first platform encompasses >65M molecular measurements spanning 45+ years of human aging, and unlocks a universe of novel biological insights and druggable mechanisms for age-related disease.

BIOAGE

Location

California, USA

Founded

2015

Funding

\$123.9M

Focus

AI/ML

Altos Labs

Altos Labs is a new biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine. Their mission is to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.

ALTOS

Location

California, USA

Founded

2021

Funding

\$3.27B

Focus

Cellular Reprogramming



Insilico Medicine

Insilico is an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging their rapidly evolving, proprietary platform across biology, chemistry and clinical development. Their Pharma.AI platform aims to bring novel breakthrough medicines to patients while decreasing costs and increasing probabilities of success.



Location	Founded	Funding	Focus
Hong Kong, China	2014	\$366.3M	AI/ML

New Limit

NewLimit is inventing medicines composed of epigenetic reprogramming factors that restore youthful function in old cells. They leverage functional assays, single cell multi-omics, and machine learning to reveal epigenetic features of aging and discover rejuvenating interventions.



Location	Founded	Funding	Focus
California, USA	2021	\$105M	Cellular Reprogramming

Retro Biosciences

Retro's mission is to increase healthy human lifespan by ten years by focusing their efforts on cellular reprogramming, autophagy, and plasma-inspired therapeutics. To support these three programs, Retro is investing heavily in single-cell multi-omics, machine-learning-based computational biology, and lab automation.



Location

California, USA

Founded

2021

Funding

\$180M

Focus

Cellular Reprogramming

Loyal

Loyal is a team of veterinarians, scientists, and dog lovers devoted to developing medicines intended to treat the underlying causes of aging in dogs. After the company proves that their medicines can extend lifespan in dogs, the company will then take what it has learned and focus on building a therapies for humans.



Location

California, USA

Founded

2019

Funding

\$38M

Focus

Pets



Life Biosciences

Life Biosciences is dedicated to developing novel therapies to extend healthy human lifespan by targeting three molecular pathways that regulate the biology of aging: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Their platform approach enables them to develop medicines with the potential to prevent, treat, and/or reverse multiple aging-related diseases, each with critical unmet needs.



Location

Mass, USA

Founded

2017

Funding

\$206.8M

Focus

DisCo

Elevian

Elevian is developing new medicines that promote recovery and regeneration. Their lead program is a recombinant protein for the treatment of stroke in the days following the event, for which there are currently no viable treatments. By promoting regeneration, Elevian's medicines have the potential to treat and prevent many aging-associated diseases.



Location

Mass, USA

Founded

2017

Funding

\$64.3M

Focus

Regenerative Medicine



AgelessRx

AgelessRx is a first of its kind longevity platform that offers the highest level of accessibility and treatments that make you look and feel better as you age. The company currently offers several treatments that consumers can purchase after submitting a medical intake form that is reviewed by a professional from their team.



Location

Michigan, USA

Founded

2019

Funding

\$4.2M

Focus

Supplements

Elysium Health

Elysium's mission is to translate critical scientific advancements in aging research into accessible health products and technologies. Working directly with the world's leading scientists, clinicians, and institutions, the company develops clinically validated solutions that address some of the most significant needs in healthcare.

ELYSIUM

Location

New York, USA

Founded

2014

Funding

\$71.2M

Focus

Supplements



07

Closing Thoughts

Just a couple decades ago, the world was concerned with overpopulation and the challenges that would come with too many humans on earth. Now, as birth rates plunge around the world, the biggest concern is how we'll adapt our societies and economies to accommodate an aging population.

Work forces, health care systems, retirement plans, insurance policies, and numerous other mega-industries will need to adapt to these changing demographics. While the challenges will be large in scale, the opportunities will be equally big for entrepreneurs, investors, and problem solvers.

At the same time, breakthroughs in biotech and improvements in global healthcare are certain to increase human healthspans and lifespans even further. People will be in the workforce longer than ever before, presenting new opportunities and challenges for employers.

We're here to track these changes and communicate the bigger picture, so that all of these developments can be seen and understood by the general public.

Subscribe to our free, once a week newsletter [here](#).

If you're an accredited investor and would like to join Spannrr in exclusive early stage investment opportunities, [apply here](#).



Spannr is proud to offer Spannr Ventures, giving members exclusive access to highly-curated longevity investments alongside a number of like-minded investors. Through our experience-led, data-driven investment selection process, you can be confident that the deals you see are some of the best opportunities in the industry.

Invest in the future of humanity.

[Learn More](#)



DISCLAIMER: None of the information within this report should be taken as investing advice, as Spannrr is just a platform to provide information and data. Furthermore, despite our best efforts to provide accurate information, it's possible that there are errors, typos, and other mistakes within this report.

While we encourage you to share this report via spannr.com, none of the material within this report, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party including by way of any form of social media, without the prior express written permission of Spannrr, Inc.

No representations or warranties whatsoever are made by the Company, the Manager or any other person or entity as to the accuracy of the information contained within this report. Furthermore, all material provided in this report and any associated document is for informational purposes only and should not be interpreted as an offer or solicitation to buy or sell securities. Spannrr, Inc. is not a licensed broker, broker dealer, investment banker, market maker, analyst, or underwriter.

